- In May 2021, Siemens launched the Somatom X.ceed, a high-resolution, high-speed CT scanner designed for challenging clinical areas. This innovation enhances Siemens' product pipeline, delivering their commitment to advancing diagnostic imaging technologies. The Somatom X.ceed is tailored to deliver precise and efficient imaging, catering to the complex demands of diverse clinical scenarios
- In April 2021, the FDA authorized the Neurolutions IpsiHand Upper Extremity Rehabilitation System by Neurolutions, Inc. This Brain-Computer-Interface (BCI) device facilitates rehabilitation for stroke patients with upper extremity disabilities, specifically addressing hand, wrist, and arm impairments. The approval underscores its potential in enhancing neurorehabilitation outcomes for individuals recovering from stroke-related motor deficits
- In April 2021, Koninklijke Philips N.V. announced a strategic partnership with Ibex Medical Analytics to collectively advance their digital pathology and A.I. solutions globally. This collaboration aims to strengthen their distribution channels, facilitating enhanced accessibility to innovative pathology solutions for hospitals, health networks, and pathology labs worldwide
- In September 2020, Hyperfine Research, Inc. obtained FDA 510(k) clearance for their groundbreaking Swoop Portable MR imaging device. This portable MRI technology redefines point-of-care imaging, allowing for on-the-spot magnetic resonance imaging. The FDA clearance signifies a significant advancement, enabling more accessible and immediate diagnostic imaging in diverse healthcare settings
- In June 2020, RapidAI achieved FDA clearance for artificial intelligence algorithms capable of swiftly analyzing brain CT scans, identifying suspected large vessel occlusions—a leading cause of severe strokes. In addition, they obtained FDA clearance for computer-assisted diagnostic software, enhancing physicians' interpretation of non-contrast CT scans, reflecting advancements in stroke diagnostics technology
